GlassScriptPhysician profile
Danica Yang
NPI 1013401736
$6,529.26
in general payments reported to CMS, 2019-2025
22 companies · $683 in 2025
The $683 reported for 2025 was more than what 77% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,452 · 2020: $184 · 2021: $287 · 2022: $523 · 2023: $408 · 2024: $992 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valley Contax, INC. | $1,375.64 | 2019 | |
| Alcon Vision LLC | $1,339.62 | 2019-2025 | Tryptyr, Eysuvis, Simbrinza |
| Glaukos Corporation | $506.55 | 2021-2024 | Ce-Marked Kxla System |
| Bausch & Lomb Americas INC. | $476.54 | 2022-2025 | Miebo, Xiidra, Lotemax Sm |
| Tarsus Pharmaceuticals, INC. | $423.93 | 2024-2025 | Xdemvy |
| Coopervision INC. | $298.98 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $246.94 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $219.53 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $187.44 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $187.08 | 2020-2025 | Acthar |
| Allergan, INC. | $169.92 | 2021-2022 | |
| Abbvie INC. | $156.14 | 2022-2024 | Durysta |
| Kala Pharmaceuticals, INC. | $147.75 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $146.06 | 2020-2023 | |
| Harrow Eye, LLC | $136.00 | 2024-2025 | Vevye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $128.88 | 2020 | |
| Shire North American Group INC | $125.00 | 2019 | |
| Oyster Point Pharma, INC. | $118.18 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $82.97 | 2022-2025 | Oxervate |
| Biotissue Holdings INC. | $24.22 | 2024 | |
| Rayner Intraocular Lenses Limited | $16.89 | 2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Aerie Pharmaceuticals, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danica Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.